Abstract
Leukemic cells from 230 children with newly diagnosed B-cell precursor ALL were tested for in vitro drug resistance to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. During follow-up, 24 relapses occurred in the 159 children with MRD <0.1% day 29. The risk of any relapse was correlated to vincristine and doxorubicin resistance, with a relative risk of 3.7 (95% CI 1.3-10.5; p=0.016) for patients resistant to both drugs. There was a significant correlation also for the subgroup with extra-medullary relapses. Our findings indicate that analysis of drug resistance can add prognostic information to other known risk-factors including MRD.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Marrow Cells / drug effects*
-
Bone Marrow Cells / metabolism
-
Bone Marrow Cells / pathology
-
Child
-
Child, Preschool
-
Chromosome Aberrations
-
Doxorubicin / pharmacology
-
Drug Resistance, Multiple*
-
Drug Resistance, Neoplasm*
-
Female
-
Follow-Up Studies
-
Humans
-
Infant
-
Male
-
Neoplasm, Residual / diagnosis
-
Neoplasm, Residual / genetics
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
-
Prednisolone / pharmacology
-
Prognosis
-
Risk Factors
-
Vincristine / pharmacology
Substances
-
Antineoplastic Agents
-
Vincristine
-
Doxorubicin
-
Prednisolone